Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Sodium And Chloride Dependent Glycine Transporter 1 Pipeline Review, H1 2018, outlays comprehensive information on the Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 Sodium and chloridedependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. It terminates the action of glycine by its high affinity sodiumdependent reuptake into presynaptic terminals. It plays a role in regulation of glycine levels in NMDA receptormediated neurotransmission. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Hematological Disorders and Metabolic Disorders which include indications Schizophrenia, Bipolar Disorder Manic Depression, Cancer Pain, Chronic Pain, Cognitive Impairment Associated With Schizophrenia CIAS, Memory Impairment, Mild Cognitive Impairment, Neuropathic Pain, Parkinsons Disease, Pervasive Developmental Disorder PDD and Thalassemia.
Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 Sodium and chloridedependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. It terminates the action of glycine by its high affinity sodiumdependent reuptake into presynaptic terminals. It plays a role in regulation of glycine levels in NMDA receptormediated neurotransmission. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Hematological Disorders and Metabolic Disorders which include indications Schizophrenia, Bipolar Disorder Manic Depression, Cancer Pain, Chronic Pain, Cognitive Impairment Associated With Schizophrenia CIAS, Memory Impairment, Mild Cognitive Impairment, Neuropathic Pain, Parkinsons Disease, Pervasive Developmental Disorder PDD and Thalassemia.
Get Free Sample copy of this Report @ https://www.24marketreports.com/request-sample/sodium-and-chloride-dependent-glycine-transporter-1-glyt1-or-solute-carrier-family-6-member-9-or-slc6a9pipeline-review-h1-2018-market-110
Furthermore, this report also reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9
The report reviews Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics and enlists all their major and minor projects
The report assesses Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9
The report reviews Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics and enlists all their major and minor projects
The report assesses Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Sodium And Chloride Dependent Glycine Transporter 1 Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9 targeted therapeutics
No comments:
Post a Comment